Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
C
Cooley
Activity from announced rounds
All recorded activity
Cooley, also named Cooley LLP, is a law firm that Steward and Superluminal identify as an investor in their announcements.
Recorded funding activity
Steward automates AML and KYC work for investor onboarding. Superluminal develops small-molecule medicines using structural biology, protein dynamics, machine learning and experiments. These disclosed investment relationships are distinct from Cooley’s separate role as legal counsel in other transactions.
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $85M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
3 in all activitySuperluminal Medicines
$60MSeries B
ParticipantFSH Technologies
FSH Technologies builds software for local governments, school districts and public agencies.
$20MSeries A
ParticipantSteward
Automates AML and KYC workflows for investor onboarding and compliance
$5MPre-Seed
Role not disclosed